Deal Announcements

Eisai Acquires Morphotek For $325 Million

Thursday, March 22, 2007 8:30:00 AM PDT | VentureDeal Staff

WOODCLIFF LAKE, NJ -- Eisai Corporation of America (ECA) announced an agreement to acquire Morphotek for $325 million.

Morphotek has developed the therapeutic use for monoclonal antibodies through the use of proprietary human antibody technologies.  The company has two clinical programs early stage trials, treatments for ovarian cancer and pancreatic cancer.

ECA has an extensive oncology research program and believes that the acquisition will expand its capabilities in the field of biologic therapeutics.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1